Influence of multimodality therapy on the management of pancreas carcinoma

J. Milburn Jessup, Marshall Posner, Mark Huberman

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Carcinoma of the pancreas has an especially grim prognosis. Only 1‐3% of patients survive for 5 years. Radical pancreaticoduodenectomy, especially for minimal disease, is currently the only chance for cure. While radiation therapy does not improve overall survival, it may improve local control following radical resection and decrease pain in locally advanced cancers. Although chemotherapy has led to significant improvements in survival in patients with locally advanced disease, the overall effect is small. When surgery, radiotherapy, and chemotherapy are administered to localized carcinomas in randomized, prospective trials, survival is significantly lengthened. Similar trials in locally advanced, unresectable pancreatic cancer also confirm the concept of synergistic interaction between therapies. Thus, pancreas carcinoma is one neoplasm where multimodality therapy has had a demonstrable, although small effect.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalSeminars in Surgical Oncology
Issue number1
StatePublished - 1993
Externally publishedYes


  • adjuvant therapy
  • radiation therapy
  • treatment synergism


Dive into the research topics of 'Influence of multimodality therapy on the management of pancreas carcinoma'. Together they form a unique fingerprint.

Cite this